Related Experiment Video

Updated: Aug 18, 2026

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric

W Debinski1, R K Puri, I Pastan

  • 1Laboratory of Molecular Targeting, Hotel-Dieu Hospital of Montreal, University of Montreal, QC, Canada.

International Journal of Cancer
|September 1, 1994
PubMed

Insights

Chimeric proteins targeting Interleukin-4 receptors (IL4R) on human tumors demonstrated specific antitumor activity. One engineered toxin, hIL4-PE38QQR, achieved transient solid tumor regression, suggesting potential for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • Interleukin-4 receptors (IL4R) are expressed on various human cancer cells, including hematopoietic and epithelial malignancies.
  • Targeting specific receptors on cancer cells is a key strategy in developing novel cancer therapies.

Purpose of the Study:

  • To evaluate the efficacy of chimeric proteins composed of human IL4 (hIL4) and Pseudomonas exotoxin A (PE) variants against IL4R-expressing human solid tumors.
  • To assess the role of the toxin's ADP-ribosylation activity in the chimeric proteins' antitumor effects.

Main Methods:

  • Construction of two chimeric toxins: hIL4-PE4E and hIL4-PE38QQR, by fusing hIL4 to mutant forms of PE.
  • Testing the chimeric toxins on human solid tumor xenografts to assess antitumor activity in an IL4R-dependent manner.
  • Inactivation of the toxin's ADP-ribosylation activity through mutagenesis to determine its contribution to efficacy.

Main Results:

  • Both hIL4-PE4E and hIL4-PE38QQR exhibited specific, IL4R-dependent, and dose-dependent antitumor activities.
  • Chimeric toxins with inactivated ADP-ribosylation activity showed no antitumor potency.
  • The hIL4-PE38QQR chimera induced a complete, albeit transient, regression of established solid tumors.

Conclusions:

  • hIL4-PE chimeric proteins targeting IL4R demonstrate specific and potent antitumor activity against solid tumors.
  • The ADP-ribosylation activity of the Pseudomonas exotoxin A component is essential for the chimeric toxins' efficacy.
  • hIL4-PE chimeric proteins warrant further investigation as a potential therapeutic strategy for human malignancies.

More Related Videos

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.